Form 4: CYTK CEO Sells 5,000 Shares Under 10b5-1 Plan

Cytokinetics President & CEO Robert I Blum sold 5,000 shares of common stock at $55.05 per share under a pre-arranged trading plan.

Summary

• Robert I Blum, President & CEO and a Director of Cytokinetics Inc. (CYTK), reported a sale of common stock.
• The transaction involved the disposition of 5,000 shares of common stock.
• The shares were sold at a price of $55.05 per share.
• The transaction occurred on October 1, 2025.
• This sale was conducted pursuant to a Rule 10b5-1(c) contract, instruction, or written plan, indicating it was pre-scheduled.
• Following the reported transaction, Mr. Blum directly beneficially owns 368,108 shares of common stock.
• Additionally, Mr. Blum indirectly beneficially owns 2,083 shares through The Bridget Blum 2003 Irrevocable Trust and 2,083 shares through The Brittany Blum 2003 Irrevocable Trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it's an insider sale, the fact that it's under a Rule 10b5-1 plan indicates it's a pre-scheduled personal financial management decision rather than a reaction to new, negative company developments. This transparency mitigates potential negative interpretations.

Positives

• The sale was executed under a Rule 10b5-1(c) plan, indicating it was pre-scheduled and not based on immediate, non-public information, which can mitigate concerns about opportunistic insider selling.

Negatives

• The transaction represents a reduction in direct insider ownership by a key executive, which some investors may interpret as a lack of confidence, despite the pre-planned nature.

Industry Context

This filing is specific to an individual insider transaction and does not provide broader industry context or trends.

Related Party Transactions

• Indirect beneficial ownership of 2,083 shares each by The Bridget Blum 2003 Irrevocable Trust and The Brittany Blum 2003 Irrevocable Trust, which are related parties to Mr. Blum.

Stakeholder Impact

• Shareholders may observe a slight reduction in insider ownership, which could be a minor factor in their investment decisions, though the 10b5-1 plan context typically lessens its impact.

Key Dates

Recommendation

The sale of 5,000 shares by the CEO, while notable, was conducted under a pre-arranged 10b5-1 plan. This suggests a planned diversification or liquidity event rather than a signal of immediate concerns about the company's prospects. Given the relatively small size compared to total holdings and the pre-planned nature, this single transaction is unlikely to warrant a change in investment thesis for a seasoned investor, thus a 'hold' recommendation is appropriate.

Keywords

CYTOKINETICS, CYTK, Robert I Blum, insider trading, Form 4, stock sale, CEO, 10b5-1 plan